Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) have earned a consensus rating of “Moderate Buy” from the seven research firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, five have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $8.00.

Several brokerages have commented on HOWL. Zacks Research upgraded shares of Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 16th. JMP Securities dropped their price objective on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a report on Thursday, August 21st. Bank of America reduced their target price on shares of Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Monday, August 25th. Citigroup reiterated a “buy” rating on shares of Werewolf Therapeutics in a report on Monday, August 25th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Wednesday, October 8th.

Insider Buying and Selling at Werewolf Therapeutics

In other Werewolf Therapeutics news, major shareholder Ansbert Gadicke sold 54,452 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $1.21, for a total transaction of $65,886.92. Following the completion of the transaction, the insider owned 5,904,720 shares of the company’s stock, valued at $7,144,711.20. This represents a 0.91% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Bioventures 2014 L.P. Mpm sold 54,452 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $1.21, for a total transaction of $65,886.92. Following the transaction, the insider directly owned 5,904,720 shares of the company’s stock, valued at $7,144,711.20. This represents a 0.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 2,150,286 shares of company stock worth $2,995,317. Corporate insiders own 23.60% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. MPM Bioimpact LLC lifted its position in Werewolf Therapeutics by 0.9% during the 1st quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock worth $2,341,000 after buying an additional 20,799 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Werewolf Therapeutics by 33.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company’s stock valued at $93,000 after acquiring an additional 23,852 shares in the last quarter. MPM Asset Management LLC increased its position in shares of Werewolf Therapeutics by 0.6% in the first quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock valued at $4,189,000 after acquiring an additional 25,688 shares during the last quarter. Quadrature Capital Ltd bought a new stake in Werewolf Therapeutics during the second quarter worth about $28,000. Finally, Bank of America Corp DE boosted its position in Werewolf Therapeutics by 1.2% during the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock valued at $2,321,000 after purchasing an additional 25,882 shares during the last quarter. Institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Stock Performance

HOWL stock opened at $1.15 on Friday. Werewolf Therapeutics has a 1-year low of $0.60 and a 1-year high of $2.39. The company has a current ratio of 3.87, a quick ratio of 5.30 and a debt-to-equity ratio of 0.73. The firm has a market cap of $55.82 million, a PE ratio of -0.71 and a beta of 0.72. The business’s 50-day moving average price is $1.60 and its two-hundred day moving average price is $1.33.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. As a group, research analysts forecast that Werewolf Therapeutics will post -1.56 earnings per share for the current year.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.